Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Heidelberg, Germany, September 22, 2017 -
Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 28, 2017 at 2:30 p.m. (ET) in New York City.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit
www.affimed.com
.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail:
IR@affimed.com
or
c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail:
a.alexandru@affimed.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Affimed N.V. via GlobeNewswire